NHS England updates CDF List
NHS England updates CDF List
NHS England has updated the Cancer Drugs Fund List. The latest version (v1.354) was uploaded to the NHS England Website on Friday 14, March 2025.
The following changes have been introduced:
Olaparib (OLAP10)
Olaparib as monotherapy for treatment adults with deleterious or suspected deleterious germline BRCA1 or 2 mutations who have HER-2 negative locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane in the adjuvant/neoadjuvant/advanced disease settings and also treated with prior endocrine-based therapy if the patient has hormone-receptor positive disease where the following criteria have been met
Moved into routine commissioning - section B of list
Trastuzumab Emtansine (TRA1)
The treatment of HER2-positive locally advanced/ unresectable or metastatic (Stage IV) breast cancer where all the following criteria are met:
Treatment criterion (#4) updated
Rucaparib (RUC4)
As maintenance treatment in patients with high grade epithelial stage III or IV ovarian, fallopian tube or primary peritoneal carcinoma who are in response following platinum-based FIRST line chemotherapy for a tumour which has a NEGATIVE status for a deleterious or suspected deleterious BRCA germline and/or somatic BRCA mutation AND a NEGATIVE or UNKNOWN status for homologous recombination deficiency as defined by the presence of genomic instability where the following criteria have been met
Date moving into routine commissioning updated